Tumor expression of Fas ligand (CD95L) and the consequences.

Walker PR; Saas P; Dietrich PY

doi:10.1016/s0952-7915(98)80225-2

Back

Journal article

Tumor expression of Fas ligand (CD95L) and the consequences.

Walker PR Laboratory of Tumour Immunology, Division of Oncology, University Hospital Geneva, 24 rue Micheli-du-Crest, CH-1211, Geneva 14, Switzerland. Paul.Walker@hcuge.ch
Saas P
Dietrich PY

1998-10-31

Published in:

Current opinion in immunology. - 1998

English Tumors of diverse origin have recently been shown to express CD95 ligand and to induce apoptosis in CD95-expressing targets in vitro; however, in vivo, enhanced tumor growth and rejection have both been observed as a consequence of either immunosuppressive or proinflammatory functions of CD95 ligand. The final in vivo outcome of CD95 ligand expression will depend upon a complex balance of interactions relevant for each tumor in its particular microenvironment.

Language